Amarin Corp. PLC Company Profile (NASDAQ:AMRN)

Analyst Ratings

Consensus Ratings for Amarin Corp. PLC (NASDAQ:AMRN) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $6.75 (187.23% upside)

Analysts' Ratings History for Amarin Corp. PLC (NASDAQ:AMRN)
Show:
DateFirmActionRatingPrice TargetActions
7/7/2016Jefferies GroupReiterated RatingBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2015SunTrust Banks Inc.UpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Goldman Sachs Group Inc.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Amarin Corp. PLC (NASDAQ:AMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.11)($0.14)$26.77 million$25.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.13)($0.10)$23.62 million$26.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.12)($0.14)$21.93 million$21.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q2($0.12)($0.15)$19.10 million$17.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.11)($0.16)$21.86 million$15.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q414($0.13)($0.11)$17.40 million$16.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.14)($0.17)$14.87 million$14.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.15)($0.14)$12.86 million$12.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.18)($0.16)$11.65 million$11.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.23)($0.26)$11.17 million$10.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.32)($0.25)$10.25 million$8.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.38)($0.26)$5.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.39)($0.41)$5.21 million$2.34 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012($0.28)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.22)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amarin Corp. PLC (NASDAQ:AMRN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.12)($0.12)($0.12)
Q4 20161($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amarin Corp. PLC (NASDAQ:AMRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Amarin Corp. PLC (NASDAQ:AMRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/1/2016John F TheroCEOBuy25,000$1.37$34,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2015John F TheroCEOBuy20,000$2.35$47,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014John F TheroInsiderBuy50,000$0.83$41,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Michael James FarrellInsiderBuy5,500$0.84$4,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Amarin Corp. PLC (NASDAQ:AMRN)
DateHeadline
07/21/16 02:30 PMAmarin Corporation PLC (NASDAQ:AMRN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 02:30 PMIs $10 Price Target Attainable For Amarin Corporation PLC (NASDAQ:AMRN)? - Investor Newswire
07/20/16 11:09 AMETF’s with exposure to Amarin Corp. Plc : July 20, 2016 -
07/20/16 10:36 AMEquity Roundup: Stock Performance Focus on Amarin Corporation PLC (NASDAQ:AMRN) - Press Telegraph
07/19/16 02:28 PMEarnings Focus and Crowd Sourced Sentiment Review for Amarin Corporation PLC (NASDAQ:AMRN) - TGP
07/19/16 02:28 PMAmarin Corporation Plc Ads (NASDAQ:AMRN) Shorted Shares Increased By 5.67% - Press Telegraph
07/19/16 02:28 PMAnalyst Rating Trends to Observe: Calithera Biosciences, Inc. (NASDAQ:CALA) , Amarin Corporation PLC (NASDAQ ... - Street Updates
07/18/16 07:22 AMShares of Amarin Corporation PLC (AMRN) Rally 5.48% - Trade Calls
07/16/16 02:29 PMAmarin Corporation Plc Ads (NASDAQ:AMRN) Shorts Decreased by 1.8% After Short Covering - Consumer Eagle
07/15/16 01:05 PMCoverage Initiated on Select Drug Manufacturers' Stocks
07/14/16 07:57 PMAnalyst Target and Average Rating Watch: Amarin Corporation PLC (NASDAQ:AMRN) - Press Telegraph
07/14/16 03:08 PMAMARIN CORP PLC\UK Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
07/14/16 02:31 PMStrong Sell Calls For Amarin Corporation PLC (NASDAQ:AMRN) At 0 - Investor Newswire
07/13/16 02:32 PMToday Amarin Corporation plc (ADR) Stock Rises - Consumer Eagle
07/13/16 02:32 PMHC Stocks Assessment: Pacific Biosciences of California (NASDAQ:PACB), Amarin Corporation plc (ADR) (NASDAQ ... - share market updates (press release)
07/13/16 02:32 PMAnalysts Actions to Focus: Relypsa, Inc. (NASDAQ:RLYP) , Amarin Corporation PLC (NASDAQ:AMRN) - Street Updates
07/12/16 06:46 AMAmarin Corporation PLC (NASDAQ:AMRN) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/11/16 02:30 PMAmarin Corp PLC (NASDAQ:AMRN) Institutional Investors Quarterly Sentiment - Consumer Eagle
07/07/16 02:28 PMIs $10 Within Reach For Amarin Corporation PLC (NASDAQ:AMRN)? - Investor Newswire
07/07/16 02:28 PMAmarin Corporation PLC (AMRN) : Analyst Rating Update - Trade Calls
07/07/16 10:26 AMCompany Stock Focus for Amarin Corporation PLC (NASDAQ:AMRN): Which Way Will Shares Head? - Press Telegraph
07/06/16 07:18 AMOption Market: Amarin Corporation plc Risk Hits An Extreme High - CML News
07/06/16 07:18 AMBroker Outlook For Amarin Corporation PLC (AMRN) - Fiscal Standard
07/06/16 07:11 AMAmarin to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - July 6, 2016 BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/06/16 -- Amarin Corporation plc(NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics ...
07/05/16 07:17 AMRecent Analysts Rating Overview: Amarin Corporation PLC (NASDAQ:AMRN) , Waters Corporation (NYSE:WAT) - Street Updates
07/04/16 02:29 PMBroker Outlook For The Week Ahead Amarin Corporation PLC (AMRN) - Fiscal Standard
07/01/16 07:42 PMAmarin Corporation PLC (NASDAQ:AMRN) Expected to Reach Highs Of $10 - Investor Newswire
07/01/16 07:42 PMCutting Edge Stocks in Focus- Amarin Corporation (NASDAQ:AMRN), Hertz Global (NYSE:HTZ), Blucora (NASDAQ ... - Seneca Globe
07/01/16 04:50 PMETF’s with exposure to Amarin Corp. Plc : July 1, 2016 -
07/01/16 02:28 PMAmarin Corporation PLC (AMRN) Updated Price Targets - FTSE News
06/30/16 03:07 PMAMARIN CORP PLC\UK Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements -
06/30/16 02:36 PMAnalyst Rating Update on Amarin Corporation PLC (AMRN) - Trade Calls
06/30/16 02:36 PMCompany Update (NASDAQ:AMRN): Amarin Corporation plc (ADR) Names Michael W. Kalb Chief Financial Officer - Smarter Analyst
06/30/16 10:20 AMAmarin Appoints Michael W. Kalb Chief Financial Officer
06/29/16 02:28 PMTime to Buy Amarin Corporation plc (ADR) After Today's Huge Increase? - Press Telegraph
06/29/16 02:28 PMAnalysts Rating updates about two Stocks: Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) , Amarin Corporation ... - Street Updates
06/28/16 02:42 PMEuropean ADRs Extend Gains as Pharma Stocks Surge - Nasdaq
06/27/16 02:48 PMThis Tiny Biopharma Has Been Bucking The Downtrend - Motley Fool
06/27/16 12:03 PMThis Tiny Biopharma Has Been Bucking The Downtrend -
06/27/16 07:14 AMNext Weeks Broker Price Targets For Amarin Corporation PLC (AMRN) - Fiscal Standard
06/24/16 02:27 PMNew Broker Ratings For Amarin Corporation PLC (AMRN) - FTSE News
06/24/16 02:27 PMAmarin Corporation plc versus Anacor Pharmaceuticals, Inc. Head to Head Compare - CML News
06/23/16 09:55 PMStrong Sell Calls Recommendations For Amarin Corporation PLC (NASDAQ:AMRN) At 0 - Investor Newswire
06/22/16 02:28 PMAmarin Corporation PLC (NASDAQ:AMRN) Analyst Rating Consensus - TheFounders Daily
06/22/16 07:17 AMBrokers Issue Average Price Target Of 3.08 On Amarin Corporation PLC (AMRN) - Fiscal Standard
06/21/16 02:26 PMAmarin Corporation plc (NasdaqGM:AMRN) Stock Momentum Hits Strength - CML News
06/20/16 02:30 PMCompany Shares of Amarin Corporation PLC Drops by -3.3% - Trade Calls
06/19/16 02:25 PMThis Weeks Broker Views For Amarin Corporation PLC (AMRN) - Fiscal Standard
06/16/16 02:27 PMCan Amarin Corporation PLC (NASDAQ:AMRN) Keep Up with Analyst Expectations? - Investor Newswire
06/15/16 07:34 PMAmarin - Vascepa Gains Protection Until At Least 2020 - Seeking Alpha

Social

About Amarin Corp. PLC

Amarin Corp. PLC logoAmarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Company markets Vascepa in the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMRN
  • CUSIP:
Key Metrics:
  • Previous Close: $2.33
  • 50 Day Moving Average: $2.18
  • 200 Day Moving Average: $1.75
  • P/E Ratio: N/A
  • P/E Growth: -0.02
  • Market Cap: $433.44M
  • Beta: 1.08
  • Current Year EPS Consensus Estimate: $-0.51 EPS
  • Next Year EPS Consensus Estimate: $-0.26 EPS
Additional Links:
Amarin Corp. PLC (NASDAQ:AMRN) Chart for Sunday, July, 24, 2016